Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

Breast

The purpose of this study is to further advance the ability to practice personalized medicine by learning which new drug agents are most effective with which types of breast cancer tumors and by learning more about which early indicators of response (tumor analysis prior to surgery via magnetic resonance imaging (MRI) images along with tissue and blood samples) are predictors of treatment success.
Breast
II
Mayer, Ingrid
NCT01042379
VICCBRE1951

Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal Cancer

Multiple Cancer Types

This trial studies how well the drug tucatinib works when given with trastuzumab and when given by itself. The participants in this trial have HER2-positive (HER2+) metastatic colorectal cancer (mCRC). 'Metastatic' means that the cancer has spread to other parts of the body. In the first part of this study, participants enrolled into Cohort A and received both tucatinib and trastuzumab. In the second part of this study, participants are randomly assigned to either Cohort B or Cohort C. Participants in Cohort B will receive tucatinib and trastuzumab. Participants in Cohort C will receive tucatinib. Participants in Cohort C who do not respond to therapy may have an option to receive tucatinib plus trastuzumab.
Colon, Rectal
II
Ciombor, Kristen
NCT03043313
VICCGI2035

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: